

**Appendix 1** to Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40 mg and 80 mg in major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. *J Psychiatry Neurosci* 2013.

DOI: 10.1503/jpn.130040

Copyright © 2013, Canadian Medical Association or its licensors.

**Table S1: Primary efficacy parameter — change from baseline to week 8 in MADRS total score, pattern-mixture model sensitivity analysis, intent-to-treat population\***

Shift parameter	Group; LSMD (95% CI) v. placebo	
	Levomilnacipran ER, 40 mg/d, <i>n</i> = 185	Levomilnacipran ER, 80 mg/d, <i>n</i> = 187
0	-3.342 (-5.453 to -1.231)	-3.138 (-5.242 to -1.034)
2	-3.263 (-5.392 to -1.134)	-3.073 (-5.242 to -0.904)
4	-3.267 (-5.371 to -1.164)	-3.043 (-5.236 to -0.850)
6	-3.319 (-5.480 to -1.157)	-2.936 (-5.136 to -0.737)
8	-3.318 (-5.624 to -1.011)	-2.727 (-4.969 to -0.485)

CI = confidence interval; ER = extended-release; LSMD = least squares mean difference; MADRS = Montgomery-Åsberg Depression Rating Scale.

\*For each shift parameter value, missing values were imputed multiple times using a pattern-mixture model assuming non-future dependence. For each imputed data set, we used a mixed-effects model for repeated-measures analysis.